The World Market for Cancer Diagnostics- (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)

Dublin, Jan. 28, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/s5lsgf/the_world_market) has announced the addition of the "The World Market for Cancer Diagnostics, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)" report to their offering.

Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence.

The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:
IVD Market for Cancer Tests Service Test Market in situ hybridization (ISH) Immunohistochemistry (IHC) FOB and Other Rapid Tests PSA, CEA and Other Markers Flow Cytometry Pap and HPV Testing Molecular Oncology Assays Tissue Microrrays Methylated DNA Circulating Tumor Cells Next-Generation Sequencing Technologies Tissue Function Tests Companion Testing, CDX Products and Deals

The Race for Prevention Supports a Market for Innovative Diagnostic Tools

Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up. New imaging tools, bioinformatics, sequencing technologies, improved histological tests are among the trends discussed in this multifaceted report. The importance of this industry is seen in the flurry of investments and financing arrangements made and the number of partnerships and purchases/mergers where one or both companies are involved in cancer diagnostics. This report contains Investments and Financing Agreements For Cancer Diagnostics Companies Selected Agreements Between Cancer Diagnostic Companies Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations Selected Acquisitions of Cancer Diagnostic Companies

Complete Market and Trend Analysis

In five previous editions. Kalorama has defined the oncology testing market, based on primary research of the market with particular attention to important market trends. These trends are more important to understand than today's numbers. Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific.

This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemia - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail.

This latest report contains detailed market data on the following IVD segments for their use in cancer diagnostics:

• IVD Market for Cancer Tests
• Service Test Market
• Next-Generation Sequencing Technologies
• Tissue Function Tests
• PSA, CEA and Other Immunoassays
• Flow Cytometry
• Pap and HPV Testing
• FOB, and Other Rapid Tests
• Molecular Oncology Assays
• Tissue Microrrays
• Methylated DNA
• In situ hybridization (ISH)
• Immunohistochemistry (IHC)
• Circulating Tumor Cells
• Companion Testing, CDX Products and Deals

Key Topics Covered:

One: Executive Summary

Two: Introduction

Three: Technologies Used In Cancer Diagnostics

Four: Cancer Diagnostics - Applications

Five: Cancer Diagnostic Markets

Six: Deals - Cancer Diagnostics

Seven: Cancer Diagnostics - Market Drivers And Challenges

Eight: In Vitro Cancer Diagnostics Market Analysis

Nine: Company Profiles: Cancer Diagnostic Companies

For more information visit http://www.researchandmarkets.com/research/s5lsgf/the_world_market

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Biotechnology, Diagnostics, Medical Imaging, In Vitro Diagnostics, Molecular Diagnostics